Insulin Pumps & AID Systems

Comparing the hardware and algorithmic logic behind modern Automated Insulin Delivery (AID) systems.

Tandem t:slim X2 (Control-IQ)

Form Factor: Durable, tubed pump with color touchscreen.

Algorithm Logic: Adjusts basal delivery and issues automatic correction boluses based on predicted 30-minute glucose levels. Target is fixed at 112.5 mg/dL (110-160 mg/dL range).

Clinical Data: DCL (Diabetes Control and Complications Trial) metrics show +11% Time in Range (TIR) for average adult cohorts.

Strengths: Highly customizable basal profiles; active correction boluses.

Omnipod 5

Form Factor: Tubeless, disposable patch pump (3-day wear) controlled via smartphone or dedicated PDM.

Algorithm Logic: Adjusts basal delivery every 5 minutes targeting a customizable range (110-150 mg/dL). Does not deliver automatic correction boluses; solely modulates basal.

Clinical Data: Pivotal trials showed significant reduction in hypoglycemia and improved TIR, particularly overnight.

Strengths: Tubeless freedom; adaptable algorithm that learns Total Daily Insulin (TDI) over time.

Medtronic MiniMed 780G

Form Factor: Durable, tubed pump.

Algorithm Logic: SmartGuard algorithm features a lower target option (100 mg/dL) and issues aggressive frequent micro-boluses for correction alongside basal modulation.

Strengths: Extended wear infusion sets (7-day); algorithm handles missed meal boluses better than competitors.

Beta Bionics iLet

Form Factor: Durable, tubed pump.

Algorithm Logic: "Bionic Pancreas". Requires only body weight to start. No carb counting required—users announce meal size as "Usual", "More", or "Less". Completely autonomous adaptation.

Strengths: Drastically reduces cognitive load; ideal for those struggling with rigorous carb counting.

The Missing Variable: Infusion Sets

Pump failure is rarely algorithmic; it is mechanical. The cannula interface is the weak link. The standard is 3-day wear (Teflon or steel). Medtronic recently introduced a 7-day extended wear set using advanced materials to prevent insulin fibrillation and occlusion. Factor site rotation and set failure rates into your cost-benefit analysis.